Bronchial Neoplasms  >>  Tecentriq (atezolizumab)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tecentriq (atezolizumab) / Roche
IMpower111 , NCT02409355 / 2014-003106-33: A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111)

Checkmark P3 IMpower111 trial of MPDL3280A monotherapy for first-line squamous NSCLC
Dec 2017 - Dec 2017: P3 IMpower111 trial of MPDL3280A monotherapy for first-line squamous NSCLC
Terminated
3
8
US, Europe, RoW
Atezolizumab, MPDL3280A; Tecentriq, Carboplatin, Cisplatin, Gemcitabine
Hoffmann-La Roche
Non-Small Cell Lung Cancer
12/17
12/17

Download Options